Stocktoria
TuHURA Biosciences, Inc./NV HURA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-07-12
TuHURA Biosciences, Inc./NV financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | — |
| R&D expense | $20.5M | $13.3M | $2.7M | $9.4M | $9.3M |
| Interest expense | $625,283 | $4.1M | — | $18,688 | — |
| Income tax | $1,600 | $3,768 | — | $0 | — |
| Net income | -$30.1M | -$21.7M | -$8.3M | -$29.3M | -$14.6M |
| EPS (diluted) | $-0.63 | $-1.21 | — | $-2.47 | — |
| Operating cash flow | -$27.6M | -$14.7M | -$7.2M | -$12.0M | -$11.9M |
| Free cash flow | -$27.7M | -$14.8M | — | -$12.0M | — |
| Cash & equivalents | $3.6M | $12.7M | $4.9M | $3.7M | $1.5M |
| Total assets | $27.4M | $20.0M | $6.2M | $4.4M | $4.0M |
| Total liabilities | $6.4M | $5.4M | $2.4M | $5.9M | $3.2M |
| Shareholders' equity | $20.9M | $14.6M | -$7.0M | -$1.6M | $731,000 |
Source: SEC EDGAR filings · CIK 0001498382 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.